Wealth Watch Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealth Watch Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3	Closed	-$1.19K	–	155
2025 Q4	$1.19K	Sell	3 -6	-67%	-$2.65K	﹤0.01%	755
2025 Q3	$4.1K	Buy	+9	New	+$3.67K	﹤0.01%	536

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealth Watch Advisors's ALNY Position: Q1 2026 in Review

Wealth Watch Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3 shares — an estimated $1.19K sold.

Wealth Watch Advisors first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $4.1K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Wealth Watch Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Wealth Watch Advisors sold 3 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.19K.
Wealth Watch Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Wealth Watch Advisors's Alnylam Pharmaceuticals position peaked at $4.1K in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Wealth Watch Advisors's 13F filing for Q1 2026, filed 15 May 2026.